Aptose Biosciences Inc. - רווח למניה בשנים עשר החודשים האחרונים APTO

High R&D costs and strict FDA oversight create barriers to entry, which this chart on GURU.Markets illustrates through the change in the rolling annual EPS. The value -36.29 forms the current metric indicator. Stable demand for myeloleukemia therapy provides revenue inertia, while active data preparation for tuspetnib confirms the high scientific concentration of Aptose Biosciences Inc. (APTO).

This metric aggregates annual net income, dividing it by the total number of shares to determine the owner's share of the final result. This indicator measures the actual efficiency of capital, stripped of the impact of share issuance. For Aptose Biosciences Inc. (APTO), which lacks operating income, the figure reflects the cash burn rate for the development of oncology therapies. The current financial status depends exclusively on external financing and clinical trials. By analyzing the rolling net income per share, an investor can see the balance between risks and growth potential.